TrialEvaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
Trial details
- Registry ID
- NCT04805671
- Phase
- Phase 2, Phase 3
Drug research
ADG20
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19NCT04805671 | IVVD | Phase 2, Phase 3 | Terminated | 2022-02-10Actual |
| Evaluation of ADG20 for the Prevention of COVID-19NCT04859517 | IVVD | Phase 2, Phase 3 | Terminated | 2022-11-04Actual |
Evaluation of ADG20 for the Prevention of COVID-19
Trial details
- Registry ID
- NCT04859517
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |